Proxy Votes Now

Home › Funds › Franklin Biotechnology Discovery Fund

Franklin Biotechnology Discovery Fund (FBDIX) proxy voting record 2025-2026

Fund family: FRANKLIN STRATEGIC SERIES · Filed by FRANKLIN STRATEGIC SERIES (CIK 872625) · SEC series S000006882

Share classes and tickers: FBDIX (C000018631), FBTDX (C000141458), FRBRX (C000128862), FTDZX (C000081539)

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 634 with, 8 against, 0 abstentions (not counted as with management). Shareholder proposals: 4 FOR, 3 AGAINST, 0 abstained, by the filing’s own vote-source field.

No item-level comparison with other FRANKLIN STRATEGIC SERIES funds is possible: no ballot item of this fund was voted by at least three other funds of the family with a clear majority.

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections3060
Audit-related790
Capital Structure690
Compensation691
Say-on-Pay670
Corporate Governance554
Other Social Issues32
Shareholder Rights and Defenses20
Environment or Climate11

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
Gilead Sciences, Inc.April 30, 2026$68M153
Amgen Inc.May 19, 2026$66M151
Regeneron Pharmaceuticals, Inc.June 12, 2026$58M70
Vertex Pharmaceuticals IncorporatedMay 13, 2026$55M141
argenx SEMay 6, 2026$47M120
argenx SENovember 18, 2025$46M10
Guardant Health, Inc.June 17, 2026$36M50
Revolution Medicines, Inc.June 18, 2026$34M40

Notable votes against management

MeetingCompanyProposalFundMgmt
April 30, 2026Gilead Sciences, Inc.To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposalForAgainst
April 30, 2026Gilead Sciences, Inc.To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor
May 19, 2026Amgen Inc.Stockholder proposal to require an independent board chairman. Shareholder proposalForAgainst
May 13, 2026Vertex Pharmaceuticals IncorporatedShareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposalForAgainst
May 4, 2026Eli Lilly and CompanyShareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposalForAgainst
May 4, 2026Eli Lilly and CompanyShareholder proposal to prepare an annual lobbying report. Shareholder proposalAgainstFor
June 30, 2026Inventiva SAAuthorize Capital Issuances for Use in Employee Stock Purchase PlansForAgainst

Search this fund’s votes by company

651 ballot items at 80 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, Franklin Biotechnology Discovery Fund (FBDIX) voted at 80 shareholder meetings of 77 companies, on 651 ballot items in all. Where management made a recommendation, the fund followed it on 98.8% of the items and voted against it 8 times. Its most frequent area of disagreement was corporate governance (4 of its votes against management). It voted on 7 shareholder proposals.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026. The interactive database shows the same votes company by company, with every other fund that voted.